Search

Artera, a developer of cancer diagnostic tools, has launched an artificial intelligence (AI) test to help prostate cancer patients make decisions between active surveillance and active treatment. The ArteraAI Prostate Test analyzes digital pathology images to estimate cancer progression and predict the benefit of treatment. The test does not make clinical recommendations but aims to support the decision-making process between patients and their physicians. The test is available in all states except New York and California, and discussions are underway with regulators for approval in those states. Medicare has set a payment rate of $700 for the AI test. The test can also predict if patients will benefit from androgen deprivation therapy (ADT) and potentially avoid its side effects. The National Comprehensive Cancer Network has included Artera as the first AI test in its Clinical Practice Guidelines in Oncology. Artera is also working on a version of the test to inform higher-risk prostate cancer patients about the duration of ADT and prognosis after prostatectomy. The company aims to eventually perform the test using digital images of pathology slides only. [Extracted from the article]